What we do
Our mission is to transform cancer care through large-scale molecularly-informed clinical research.
Traditional oncology drug development and clinical care paradigms, emphasizing uniformity of management, are ill-suited to the precision oncology era of patient-centered trials and care. We believe a new model that integrates molecular profiling and cutting-edge clinical research will dramatically improve treatment options, while speeding the path to drug approvals.
Our goal is to create a new standard of care for cancer patients, one where molecular profiling, clinical trial participation and continuous learning to inform care and research are the norm.
Strata Oncology was founded in 2016 by leading physicians and scientists with a shared vision for realizing the promise of precision medicine for cancer patients. Since then we have raised $38 million in venture capital and partnered with leading health systems and biopharmaceutical companies to create a future in which all cancer patients have access to the best precision care.
Board of Directors
Keith Flaherty, MD
Dan Rhodes, PhD
Executive Director, Pfizer Ventures
Co-founder, Strata Oncology, Professor, Harvard Medical School, Oncologist, MGH
Founder and Managing Director, Arboretum Ventures
President & CEO, Co-founder, Strata Oncology
Investment Principal, Merck Global Health Innovation Fund
Director, Venture Capital, Baird Capital
Founder & CEO, NeuMoDx Molecular